CORIS BIOCONCEPT
ActiveSummary
CORIS BIOCONCEPT has been active since 1996 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €5.4m and a net result of -€471,288. Equity remains stable across the filed fiscal years (±0.4% per year). Its solvency ranks better than 74% of 1246 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.1% (very low).
Checked score
Score 2024
Axes · tick = 2023
Profitability47▲+39
Solvency100=
Growth52=
Track record100
Bankruptcy probability, 12 months
0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €450,000 at 30 days acceptable
Liquidity ample (current ratio 5.39 against 7.14 in 2023; short-term debt: 14.7% and cash: 23.4% of total assets), and 21.4% of the assets are financed with debt.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 86
Relative position
BE, all sectors
reference
Human health activities (NACE 86)
about 87% fewer bankruptcies
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Persistent losses
Two consecutive loss-making years (2023 and 2024); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2024Net result per financial year
18192021222324
2018 to 2024 · latest year -€471,288
neutral · Filed after the deadline
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 25-09-2025, 56 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 9 filingsDeviation from the deadline
2025
not confirmed
2024
56 d late
2023
20 d late
2022
29 d late
2021
30 d late
2020
79 d late
2019
115 d late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 6 accounts on average 55 days after the deadline; the sector median for financial year 2024 is 7 days before the deadline, and 36% of the sector filed late.
Checked, nothing found (1)
History
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Is the workforce growing, and do people stay?Employer check Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What other support did companies like this one receive, and it did not?Subsidies
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2024, full schema
In the rankings
#3 company by total assets in Gembloux, Health and social work sector#3 company by equity in Gembloux, Health and social work sector#10 oldest company in Gembloux, Health and social work sector
Turnover
€5.2m▼ 12.6%
2023 · €6.0m
EBIT margin
-8.2%▲ 6.3pp
2023 · -14.5%
Net result
-€471,288▲ 44.7%
2023 · -€852,803
Working capital
€4.5m▼ 20.9%
2023 · €5.6m
Trend over the years
In euros
In per cent
Ratio
In full-time equivalents (FTE)
In euros
No line ticked in this group.
In per cent
No line ticked in this group.
Ratio
No line ticked in this group.
In full-time equivalents (FTE)
No line ticked in this group.
Untick a line to hide it. Point at a year (or use the arrow keys on the chart) for the exact figures; the table below gives them all.Sector: the middle half (P25 to P75) of NACE 86, Human health activities, each year against the same schema; no band under 30 filings. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20202021202220232024
Turnover€6.0m€5.2m▼ 12.6%
Operating result€7.6m▲ 12,918%-€0.4m-€0.1m▲ 72.2%-€0.9m▼ 752%-€0.4m▲ 50.5%
Net result€6.9mabove the sector's middle half▲ 3,281%-€0.4mbelow the sector's middle half-€0.03mbelow the sector's middle half▲ 93.1%-€0.9mbelow the sector's middle half▼ 3,038%-€0.5mbelow the sector's middle half▲ 44.7%
EBIT margin-14.5%-8.2%▲ 6.3pp
Equity€7.9mabove the sector's middle half▲ 1,518%€7.0mabove the sector's middle half▼ 11.6%€7.0mabove the sector's middle half▼ 0.3%€5.9mabove the sector's middle half▼ 15.0%€5.4mabove the sector's middle half▼ 8.3%
Total assets€12.0mabove the sector's middle half▲ 229%€9.2mabove the sector's middle half▼ 22.9%€8.7mabove the sector's middle half▼ 6.0%€7.6mabove the sector's middle half▼ 12.3%€6.9mabove the sector's middle half▼ 9.4%
Debt€4.1m▲ 29.7%€2.3m▼ 44.8%€1.7m▼ 23.5%€1.7m▼ 1.4%€1.5m▼ 13.3%
Working capital€8.4mabove the sector's middle half▲ 364%€6.8mabove the sector's middle half▼ 18.3%€7.0mabove the sector's middle half▲ 2.1%€5.6mabove the sector's middle half▼ 19.2%€4.5mabove the sector's middle half▼ 20.9%
Solvency65.9%within the sector's middle half▲ 52.5pp75.6%within the sector's middle half▲ 9.7pp80.1%above the sector's middle half▲ 4.5pp77.7%within the sector's middle half▼ 2.5pp78.6%within the sector's middle half▲ 1.0pp
Current ratio3.95within the sector's middle half▲ 1.335.04within the sector's middle half▲ 1.097.09above the sector's middle half▲ 2.057.14above the sector's middle half▲ 0.055.39above the sector's middle half▼ 1.75
Return on assets (ROA)57.3%above the sector's middle half▲ 51.7pp-4.3%below the sector's middle half▼ 61.6pp-0.3%below the sector's middle half▲ 4.0pp-11.2%below the sector's middle half▼ 10.9pp-6.8%below the sector's middle half▲ 4.4pp
Staff (FTE)31.5above the sector's middle half▲ 11.3%30.2above the sector's middle half▼ 4.1%29.8above the sector's middle half▼ 1.3%26.6above the sector's middle half▼ 10.7%31.5above the sector's middle half▲ 18.4%
above
within
below
the middle half (P25 to P75) of NACE 86, Human health activities, each year against the same schema; no band under 30 filings.
Why a figure moved sharply
- 2023 Net result -3,038% on 2022. The accounts now follow the abbreviated schema, last year the full schema.
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €430,038 in 2024 against €867,918 in 2023; the loss shrinks.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €6.9m
Fixed assets
€1.4m ▲ 34.1%
Current assets
€5.5m ▼ 16.4%
Equity and liabilities €6.9m
Equity
€5.4m ▼ 8.3%
Debt
€1.5m ▼ 13.3%
Debt's share of the balance-sheet total falls from 22.3% to 21.4%. Equity and debt are lower.
Key figures and ratios
EBITDA
€298,827▲
2023 · -€97,525
Cash flow
€257,577▲
2023 · -€82,410
Quick ratio
4.33▼
2023 · 5.76
Debt to equity
0.27▼
2023 · 0.29
ROE
-8.7%▲
2023 · -14.4%
Interest coverage
4.75▲
2023 · -2.62
Debt ≤ 1 year
€1.0m▲
2023 · €918,435
Debt > 1 year
€455,188▼
2023 · €634,818
Income taxes
€633▼
2023 · €874
Staff costs
€2.1m▲
2023 · €1.9m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 8,612 companies that looked in July 2024 the way this one looks now, 0.4% went bankrupt within 24 months and 94% are still going.
- Small
- 20 years or older
- solvency 30% or more
- a small loss
0.4%
went bankrupt
5.1%
stopped otherwise
94%
still going
A further 0.2% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a bankruptcy probability of 0.1% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,341 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 1.0% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 8,612 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Turnover70 | - | - | - | €6.0m | €5.2m | ▼ 12.6% |
| Non-recurring operating income76A | - | - | - | €0.01m | €0.003m | ▼ 69.0% |
| Goods, raw materials, services and sundry goods60/61 | - | - | - | €4.2m | €3.6m | ▼ 12.9% |
| Remuneration, social security and pensions62 | - | €1.8m | €2.0m | €1.9m | €2.1m | ▲ 12.2% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €1.4m | €1.3m | €0.9m | €0.8m | €0.7m | ▼ 5.4% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | - | - | €0.04m | €0.02m | ▼ 36.6% |
| Other operating charges640/8 | - | €0.002m | €0.003m | €0.005m | €0.002m | ▼ 66.4% |
| Non-recurring operating charges66A | - | - | €417 | €0.003m | €0.006m | ▲ 71.5% |
| Gross operating margin9900 | €10.8m | €2.7m | €2.8m | €1.8m | €2.4m | ▲ 33.4% |
| Operating profit (loss)9901 | €7.6m | -€0.4m | -€0.1m | -€0.9m | -€0.4m | ▲ 50.5% |
| Financial income75/76B | - | €0.04m | €0.1m | €0.05m | €0.02m | ▼ 55.6% |
| Recurring financial income75 | €0.01m | €0.03m | €0.1m | €0.05m | €0.02m | ▼ 51.6% |
| Non-recurring financial income76B | - | €0.01m | - | €0.004m | - | - |
| Financial charges65/66B | - | €0.06m | €0.05m | €0.04m | €0.06m | ▲ 69.7% |
| Recurring financial charges65 | €0.04m | €0.03m | €0.05m | €0.04m | €0.06m | ▲ 68.9% |
| Non-recurring financial charges66B | - | €0.03m | - | €0.001m | €0.002m | ▲ 104% |
| Profit (loss) for the period before taxes9903 | €7.6m | -€0.4m | -€0.03m | -€0.9m | -€0.5m | ▲ 44.8% |
| Income taxes67/77 | €0.7m | €385 | €0.001m | €0.001m | €0.001m | ▼ 27.6% |
| Profit (loss) for the period9904 | €6.9m | -€0.4m | -€0.03m | -€0.9m | -€0.5m | ▲ 44.7% |
| Transfer from tax-exempt reserves789 | - | - | - | €0.3m | €0.8m | ▲ 164% |
| Profit (loss) for the period to be appropriated9905 | €4.9m | -€0.4m | -€0.03m | -€0.6m | €0.3m | ▲ 155% |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €12.0m | €9.2m | €8.7m | €7.6m | €6.9m | ▼ 9.4% |
| Fixed assets21/28 | €0.8m | €0.7m | €0.6m | €1.1m | €1.4m | ▲ 34.1% |
| Intangible fixed assets21 | €0.4m | €0.3m | €0.2m | €0.1m | €0.08m | ▼ 27.3% |
| Tangible fixed assets22/27 | €0.4m | €0.4m | €0.4m | €1.0m | €1.3m | ▲ 41.1% |
| Plant, machinery and equipment23 | - | €0.3m | €0.2m | €0.3m | €0.2m | ▼ 22.8% |
| Furniture and vehicles24 | - | €0.03m | €0.1m | €0.1m | €0.07m | ▼ 35.9% |
| Leasing and similar rights25 | - | €0.03m | €0.02m | €0.5m | €0.4m | ▼ 10.0% |
| Other tangible fixed assets26 | - | €0.002m | €0.003m | €0.1m | €0.2m | ▲ 48.8% |
| Assets under construction and advance payments27 | - | - | - | - | €0.5m | - |
| Financial fixed assets28 | €0.03m | €0.03m | €0.03m | €0 | - | - |
| Current assets29/58 | €11.2m | €8.5m | €8.1m | €6.6m | €5.5m | ▼ 16.4% |
| Amounts receivable after more than one year29 | - | €0.004m | €1.1m | €1.2m | €1.2m | ▼ 0.3% |
| Other amounts receivable291 | - | €0.004m | €1.1m | €1.2m | €1.2m | ▼ 0.3% |
| Stocks and contracts in progress3 | €1.4m | €1.4m | €1.4m | €1.3m | €1.1m | ▼ 15.4% |
| Stocks30/36 | - | €1.4m | €1.4m | €1.3m | €1.1m | ▼ 15.4% |
| Amounts receivable within one year40/41 | €2.5m | €3.3m | €1.8m | €1.3m | €1.6m | ▲ 17.8% |
| Trade receivables40 | - | €0.7m | €1.3m | €1.0m | €1.5m | ▲ 52.5% |
| Other amounts receivable41 | - | €2.6m | €0.5m | €0.4m | €0.1m | ▼ 73.8% |
| Current investments50/53 | €0.001m | €0.001m | €0.001m | €0.001m | €0.001m | = |
| Cash at bank and in hand54/58 | €7.3m | €3.7m | €3.7m | €2.7m | €1.6m | ▼ 40.9% |
| Deferred charges and accrued income490/1 | - | €0.07m | €0.07m | €0.03m | €0.03m | ▲ 4.0% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €12.0m | €9.2m | €8.7m | €7.6m | €6.9m | ▼ 9.4% |
| Equity10/15 | €7.9m | €7.0m | €7.0m | €5.9m | €5.4m | ▼ 8.3% |
| Contributions10/11 | €0.3m | €0.3m | €0.3m | €0.3m | €0.3m | = |
| Reserves13 | €2.1m | €4.7m | €4.7m | €4.7m | €4.7m | = |
| Non-distributable reserves130/1 | - | €0.03m | €0.03m | €0.03m | €0.03m | = |
| Reserves not available under the articles1311 | - | €0.03m | €0.03m | €0.03m | €0.03m | = |
| Tax-exempt reserves132 | - | €4.7m | €2.1m | €1.8m | €1.0m | ▼ 43.9% |
| Distributable reserves133 | - | - | €2.6m | €2.9m | €3.7m | ▲ 26.5% |
| Profit (loss) carried forward14 | €4.8m | €1.8m | €1.7m | €0.9m | €0.4m | ▼ 53.2% |
| Investment grants15 | - | €0.2m | €0.2m | €0.04m | €0.03m | ▼ 41.4% |
| Amounts payable17/49 | €4.1m | €2.3m | €1.7m | €1.7m | €1.5m | ▼ 13.3% |
| Amounts payable after more than one year17 | €1.2m | €0.6m | €0.4m | €0.6m | €0.5m | ▼ 28.3% |
| Financial debts170/4 | - | €0.6m | €0.4m | €0.6m | €0.5m | ▼ 28.3% |
| Amounts payable within one year42/48 | €2.8m | €1.7m | €1.1m | €0.9m | €1.0m | ▲ 10.8% |
| Current portion of amounts payable after more than one year42 | - | €0.3m | €0.4m | €0.3m | €0.2m | ▼ 28.2% |
| Trade debts44 | €1.3m | €1.2m | €0.5m | €0.5m | €0.5m | ▲ 19.1% |
| Suppliers440/4 | - | €1.2m | €0.5m | €0.5m | €0.5m | ▲ 19.1% |
| Taxes, remuneration and social security45 | - | €0.2m | €0.3m | €0.2m | €0.3m | ▲ 39.4% |
| Taxes450/3 | - | €0.004m | €0.02m | €0.01m | €0.02m | ▲ 23.5% |
| Remuneration and social security454/9 | - | €0.2m | €0.3m | €0.2m | €0.3m | ▲ 40.4% |
| Other amounts payable47/48 | - | €0.003m | €0.008m | €0.003m | €0.002m | ▼ 15.0% |
| Accrued charges and deferred income492/3 | - | €0.006m | €0.2m | €0.1m | €0.002m | ▼ 98.5% |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €6.9m | -€0.4m | -€0.03m | -€0.9m | -€0.5m | ▲ 44.7% |
| + Depreciation and write-downs630 | €1.4m | €1.3m | €0.9m | €0.8m | €0.7m | ▼ 5.4% |
| Operating cash flow (approximation) | €8.3m | €0.9m | €0.9m | -€0.08m | €0.3m | ▲ 413% |
| Investment in fixed assets (approximation) | - | -€1.2m | -€0.8m | -€1.3m | -€1.1m | ▲ 13.9% |
| Change in cash | - | -€3.5m | -€0.03m | -€1.0m | -€1.1m | ▼ 14.5% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2025
25-09
NBB filing
Annual accounts filed
fiscal year 2024 · full schema · 56 days late
27-05
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema · 20 days late
2024
20-08
NBB filing
Annual accounts filed
fiscal year 2023 · full schema · 20 days late
2023
31-12
Financial
Weakest financial yearnet -€852,803
Net result drops to -€852,803, the lowest in the series; recovery starts the following year.
29-08
NBB filing
Annual accounts filed
fiscal year 2022 · full schema · 29 days late
2022
30-08
NBB filing
Annual accounts filed
fiscal year 2021 · full schema · 30 days late
2021
18-10
NBB filing
Annual accounts filed
fiscal year 2020 · full schema · 79 days late
2020
31-12
Financial
Highest result since 2018net €6.9m ▲3,281%
Operating result €7.6m, net result €6.9m, both a record.
31-12
Financial
Equity above €5mEq €7.9m ▲1,518%
2 profitable years in a row build equity to €7.9m.
23-11
NBB filing
Annual accounts filed
fiscal year 2019 · full schema · 115 days late
2019
31-12
Financial
Back to profitnet €203,247
Net result €203,247 after one loss-making year.
29-08
NBB filing
Annual accounts filed
fiscal year 2018 · full schema · 29 days late
2018
28-07
NBB filing
Annual accounts filed
fiscal year 2017 · full schema
2017
28-08
NBB filing
Annual accounts filed
fiscal year 2016 · full schema · 28 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 12 acts read
About the unread acts
We know of 12 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
No directors read yet: 0 of 12 Gazette acts processed. See the function holders in the CBE →
Location & real-estate footprint
Registered office, Gembloux · 2 establishment units since 1996
Ground area
1.1 ha
Building footprint
996 m²
Volume, LiDAR
9,011 m³
2 parcels, Wallonia · tallest building 16.5 m, ±3 floors. Linked by address, not a title deed.
2 establishment units
Rue Jean Sonet,Isnes 4, 5032 Gembloux
since 1996unit no. 2.078.889.647
Coris Bioconcept
since 2023unit no. 2.340.526.955
2 parcels
Wallonia
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 92065B0050/00V003 | Wallonia | 6,391 m² | - | - |
| 92065B0056/00Z002 | Wallonia | 4,608 m² | 1 · 996 m² | 16.5 m · 3 fl. |
Linked by address, not proof of ownership
Good to know
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Structure & network
Owners and holdings
1 ownerChain of control
- Coris Holdings
- CORIS BIOCONCEPT
Highest known parent: Coris Holdings. The sources do not say who stands above it.
Owners 1
- Coris Holdingsparent100%
Holdings 0
No holding stated in the accounts, acts or LEI register we read.
According to the annual accounts of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
No directors read yet: 0 of 12 Gazette acts processed.
Subsidies and aid
Federal government
2024 to 2025 · 2 entries · €154,551 in total| Year | Department | Transactions | Amount |
|---|---|---|---|
| 2025 | Defensie | 1 | €38,638 |
| 2024 | Defensie | 1 | €115,913 |
Budget allocations
European research
10 projects · 1 as coordinator · €3.4m EU contributionProjects
Chips for Life
Nanotherapeutics for antibiotic resistant emerging bacterial pathogens
Innovative and Smart Printed Electronics based on Multifunctionalized Paper: from Smart Labelling to Point of Care Bioplatforms
Portable Automated Water Analyser for Viruses
Viral Haemorrhagic Fever: Modern Approaches for developing bedside Rapid Diagnostics
Show 5 more projects
Syndromic approach to Neglected Infectious Diseases (NID) at primary health care level: an international collaboration on integrated diagnostic-treatment platforms
Ebola Virus: Modern Approaches for developing bedside Rapid Diagnostics – Sofia ref.: 115843
Control of leishmaniasis, from bench to bedside and community
Crimean Congo Hemorrhagic Fever; Modern Approaches to Diagnostics, Surveillance, Prevention, Therapy and Preparedness
Training the next generation of scientists on cell surface Glycans from Gram-negative gut microbiota as molecular keys to decOde the gut-immune-brain Axis
Similar companies · same sector, comparable size
Vlaamse Vereniging voor Respiratoire Gezondheidszorg en Tuberculosebestrijding
BE 0422.695.118
Leuven · Eq €6.8m
VALAURBEN
BE 0649.427.074
Mons · Eq €3.8m
Permanence Soins àDomicile
BE 0445.266.919
Namur · Eq €8.0m
ATTENTIA Preventie & bescherming
BE 0409.440.463
Sint-Agatha-Berchem · Eq €3.2m
Dr. Peter Vandergoten, Cardiologie
BE 0806.516.297
Overijse · Eq €3.0m
Of 10,428 companies in this sector we hold annual accounts for 885. 118 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Company details
Identification
Legal formPrivate limited company
Founded16-10-1996
Fiscal year end31-12
Activities, NACEBEL 2025
46460Wholesale of pharmaceutical and medical goods
86995Nutrition and dietetics services
47741Retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses
E-invoicing
Reachable via Peppol
Peppol ID
0208:0459020430
Also
9925:BE0459020430
Registered
01-12-2025
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 1 October 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.